
Final Rule on Labeling Changes Pushed Back to July 2016
FDA sets a July 2016 deadline for the final version of the rule on labeling changes for approved drugs and biologics.
The deadline for FDA’s final rule, Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products, has been extended to July 2016 according to a
According to FDA, 80% of drugs in the marketplace are generic drugs approved in ANDAs. ANDA holders, however, are not allowed to use the changes being effected (CBE) supplement process NDA and BLA holders use to update product labeling to reflect updated safety information. The notice states that, “this regulatory difference recently has been determined to mean that an individual can bring a product liability action for ‘failure to warn’ against an NDA holder, but generally not an ANDA holder. This may alter the incentives for generic-drug manufacturers to comply with current requirements to conduct robust postmarketing surveillance, evaluation, and reporting, and to ensure that their product labeling is accurate and up-to-date. Accordingly, there is a need for ANDA holders to be able to independently update product labeling to reflect certain newly acquired safety information as part of the ANDA holder's independent responsibility to ensure that its product labeling is accurate and up to date.”
FDA hopes the rule would allow for timely communication of safety related labeling changes and encourage generic-drug companies to work actively with the agency. The Food, Drug, and Cosmetic Act gives FDA the authority over the labeling for drugs and biologic products.
In a
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.